The management of advanced endometrial cancer (EC) has been transformed by immunotherapy, raising a pivotal clinical challenge: selecting patients with mismatch repair-deficient (dMMR) disease for intensive dual PD-1/CTLA-4 blockade versus standard PD-1 monotherapy. This evidence concerns the gene CTLA4 and endometrial cancer.